Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 5/2014

Open Access 01-09-2014 | Original Article

Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation

Authors: Yoko Nakajima, Judith Meijer, Doreen Dobritzsch, Tetsuya Ito, Rutger Meinsma, Nico G. G. M. Abeling, Jeroen Roelofsen, Lida Zoetekouw, Yoriko Watanabe, Kyoko Tashiro, Tomoko Lee, Yasuhiro Takeshima, Hiroshi Mitsubuchi, Akira Yoneyama, Kazuhide Ohta, Kaoru Eto, Kayoko Saito, Tomiko Kuhara, André B. P. van Kuilenburg

Published in: Journal of Inherited Metabolic Disease | Issue 5/2014

Login to get access

Abstract

β-ureidopropionase (βUP) deficiency is an autosomal recessive disease characterized by N-carbamyl-β-amino aciduria. To date, only 16 genetically confirmed patients with βUP deficiency have been reported. Here, we report on the clinical, biochemical and molecular findings of 13 Japanese βUP deficient patients. In this group of patients, three novel missense mutations (p.G31S, p.E271K, and p.I286T) and a recently described mutation (p.R326Q) were identified. The p.R326Q mutation was detected in all 13 patients with eight patients being homozygous for this mutation. Screening for the p.R326Q mutation in 110 Japanese individuals showed an allele frequency of 0.9 %. Transient expression of mutant βUP enzymes in HEK293 cells showed that the p.E271K and p.R326Q mutations cause profound decreases in activity (≤ 1.3 %). Conversely, βUP enzymes containing the p.G31S and p.I286T mutations possess residual activities of 50 and 70 %, respectively, suggesting we cannot exclude the presence of additional mutations in the non-coding region of the UPB1 gene. Analysis of a human βUP homology model revealed that the effects of the mutations (p.G31S, p.E271K, and p.R326Q) on enzyme activity are most likely linked to improper oligomer assembly. Highly variable phenotypes ranging from neurological involvement (including convulsions and autism) to asymptomatic, were observed in diagnosed patients. High prevalence of p.R326Q in the normal Japanese population indicates that βUP deficiency is not as rare as generally considered and screening for βUP deficiency should be included in diagnosis of patients with unexplained neurological abnormalities.
Appendix
Available only for authorised users
Literature
go back to reference Assmann B, Gohlich-Ratmann G, Wagner L, Moolenaar S, Engelke U, Wevers R, Voit T, Hoffmann GF (1998) Presumptive ureidopropionase deficiency as a new defect in pyrimidine catabolism found with in vitro H-NMR spectroscopy. J Inherit Metab Dis 21:Suppl 2 Assmann B, Gohlich-Ratmann G, Wagner L, Moolenaar S, Engelke U, Wevers R, Voit T, Hoffmann GF (1998) Presumptive ureidopropionase deficiency as a new defect in pyrimidine catabolism found with in vitro H-NMR spectroscopy. J Inherit Metab Dis 21:Suppl 2
go back to reference Assmann B, Gohlich G, Baethmann M et al (2006) Clinical findings and a therapeutic trial in the first patient with beta-ureidopropionase deficiency. Neuropediatrics 37(1):20–25PubMedCrossRef Assmann B, Gohlich G, Baethmann M et al (2006) Clinical findings and a therapeutic trial in the first patient with beta-ureidopropionase deficiency. Neuropediatrics 37(1):20–25PubMedCrossRef
go back to reference Begriche K, Massart J, Fromenty B (2010) Effects of beta-aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity. Fundam Clin Pharmacol 24(3):269–282PubMedCrossRef Begriche K, Massart J, Fromenty B (2010) Effects of beta-aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity. Fundam Clin Pharmacol 24(3):269–282PubMedCrossRef
go back to reference DeLano WL. 2002. The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, USA.http://www.pymol.org DeLano WL. 2002. The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, USA.http://​www.​pymol.​org
go back to reference Dipple KM, McCabe ER (2000) Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 66(6):1729–1735PubMedCentralPubMedCrossRef Dipple KM, McCabe ER (2000) Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 66(6):1729–1735PubMedCentralPubMedCrossRef
go back to reference Fidlerova J, Kleiblova P, Kormunda S, Novotny J, Kleibl Z (2012) Contribution of the beta-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity. Pharmacol Rep 64(5):1234–1242PubMedCrossRef Fidlerova J, Kleiblova P, Kormunda S, Novotny J, Kleibl Z (2012) Contribution of the beta-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity. Pharmacol Rep 64(5):1234–1242PubMedCrossRef
go back to reference Huang M, Graves LM (2003) De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci 60(2):321–336PubMedCrossRef Huang M, Graves LM (2003) De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci 60(2):321–336PubMedCrossRef
go back to reference Kuhara T, Ohse M, Inoue Y, Shinka T (2009) Five cases of beta-ureidopropionase deficiency detected by GC/MS analysis of urine metabolome. J Mass Spectrom 44(2):214–221PubMedCrossRef Kuhara T, Ohse M, Inoue Y, Shinka T (2009) Five cases of beta-ureidopropionase deficiency detected by GC/MS analysis of urine metabolome. J Mass Spectrom 44(2):214–221PubMedCrossRef
go back to reference Lundgren S, Lohkamp B, Andersen B, Piskur J, Dobritzsch D (2008) The crystal structure of beta-alanine synthase from Drosophila melanogaster reveals a homooctameric helical turn-like assembly. J Mol Biol 377(5):1544–1559PubMedCrossRef Lundgren S, Lohkamp B, Andersen B, Piskur J, Dobritzsch D (2008) The crystal structure of beta-alanine synthase from Drosophila melanogaster reveals a homooctameric helical turn-like assembly. J Mol Biol 377(5):1544–1559PubMedCrossRef
go back to reference Matthews MM, Liao W, Kvalnes–Krick KL, Traut TW (1992) b-Alanine synthase: purification and allosteric properties. Arch Biochem Biophys 293:254–263 Matthews MM, Liao W, Kvalnes–Krick KL, Traut TW (1992) b-Alanine synthase: purification and allosteric properties. Arch Biochem Biophys 293:254–263
go back to reference Nagasawa T, Wiesner M, Nakamura T, Iwahara H, Yoshida T, Gekko K (2000) Nitrilase of Rhodococcus rhodochrous J1 - Conversion into the active form by subunit association. Eur J Biochem 267:138–144 Nagasawa T, Wiesner M, Nakamura T, Iwahara H, Yoshida T, Gekko K (2000) Nitrilase of Rhodococcus rhodochrous J1 - Conversion into the active form by subunit association. Eur J Biochem 267:138–144
go back to reference Ohse M, Matsuo M, Ishida A, Kuhara T (2002) Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine. J Mass Spectrom 37(9):954–962PubMedCrossRef Ohse M, Matsuo M, Ishida A, Kuhara T (2002) Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine. J Mass Spectrom 37(9):954–962PubMedCrossRef
go back to reference Pace HC, Brenner C. (2001) The nitrilase superfamily: classification, structure and function. Genome Biol 2(1):REVIEWS0001 Pace HC, Brenner C. (2001) The nitrilase superfamily: classification, structure and function. Genome Biol 2(1):REVIEWS0001
go back to reference Schmieden V, Betz H (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol Pharmacol 48(5):919–927PubMed Schmieden V, Betz H (1995) Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol Pharmacol 48(5):919–927PubMed
go back to reference Signore AP, Zhang F, Weng Z, Gao Y, Chen J (2008) Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J Neurochem 106(5):1977–1990PubMedCentralPubMedCrossRef Signore AP, Zhang F, Weng Z, Gao Y, Chen J (2008) Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J Neurochem 106(5):1977–1990PubMedCentralPubMedCrossRef
go back to reference Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM (2005) Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet 76(6):911–924PubMedCentralPubMedCrossRef Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM (2005) Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet 76(6):911–924PubMedCentralPubMedCrossRef
go back to reference Stevenson DE, Feng R, Dumas F, Groleau D, Mihoc A, Storer AC (1992) Mechanistic and structural studies on Rhodococcus ATCC 39484 nitrilase. Biotechnol Appl Biochem.15:283–302 Stevenson DE, Feng R, Dumas F, Groleau D, Mihoc A, Storer AC (1992) Mechanistic and structural studies on Rhodococcus ATCC 39484 nitrilase. Biotechnol Appl Biochem.15:283–302
go back to reference Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2008) Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 18(1):25–35PubMedCrossRef Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2008) Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 18(1):25–35PubMedCrossRef
go back to reference Thuku RN, Weber BW, Varsani A, Sewell BT (2007) Post-translational cleavage of recombinantly expressed nitrilase from Rhodococcus rhodochrous J1 yields a stable, active helical form. FEBS J 274:2099–2108 Thuku RN, Weber BW, Varsani A, Sewell BT (2007) Post-translational cleavage of recombinantly expressed nitrilase from Rhodococcus rhodochrous J1 yields a stable, active helical form. FEBS J 274:2099–2108
go back to reference Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140(1):1–22PubMedCrossRef Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140(1):1–22PubMedCrossRef
go back to reference van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950PubMedCrossRef van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950PubMedCrossRef
go back to reference Van Kuilenburg ABP, Van Lenthe H, Van Gennip AH (1999) A radiochemical assay for beta-ureidopropionase using radiolabeled N-carbamyl-beta-alanine obtained via hydrolysis of [2-(14)C]5, 6-dihydrouracil. Anal Biochem 272(2):250–253PubMedCrossRef Van Kuilenburg ABP, Van Lenthe H, Van Gennip AH (1999) A radiochemical assay for beta-ureidopropionase using radiolabeled N-carbamyl-beta-alanine obtained via hydrolysis of [2-(14)C]5, 6-dihydrouracil. Anal Biochem 272(2):250–253PubMedCrossRef
go back to reference van Kuilenburg ABP, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705–4712PubMed van Kuilenburg ABP, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705–4712PubMed
go back to reference van Kuilenburg ABP, Meinsma R, Zonnenberg BA et al (2003) Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9(12):4363–4367PubMed van Kuilenburg ABP, Meinsma R, Zonnenberg BA et al (2003) Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9(12):4363–4367PubMed
go back to reference van Kuilenburg ABP, Meinsma R, Beke E et al (2004a) beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet 13(22):2793–2801PubMedCrossRef van Kuilenburg ABP, Meinsma R, Beke E et al (2004a) beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet 13(22):2793–2801PubMedCrossRef
go back to reference van Kuilenburg ABP, Stroomer AE, Van Lenthe H, Abeling NG, Van Gennip AH (2004b) New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 379(Pt 1):119–124PubMedCentralPubMedCrossRef van Kuilenburg ABP, Stroomer AE, Van Lenthe H, Abeling NG, Van Gennip AH (2004b) New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 379(Pt 1):119–124PubMedCentralPubMedCrossRef
go back to reference van Kuilenburg ABP, van Lenthe H, van Cruchten A, Kulik W (2004c) Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry. Clin Chem 50(1):236–238PubMedCrossRef van Kuilenburg ABP, van Lenthe H, van Cruchten A, Kulik W (2004c) Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry. Clin Chem 50(1):236–238PubMedCrossRef
go back to reference van Kuilenburg ABP, Stroomer AE, Bosch AM, Duran M (2008) Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency. Nucleosides, Nucleotides Nucleic Acids 27(6):825–829PubMedCrossRef van Kuilenburg ABP, Stroomer AE, Bosch AM, Duran M (2008) Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency. Nucleosides, Nucleotides Nucleic Acids 27(6):825–829PubMedCrossRef
go back to reference van Kuilenburg ABP, Dobritzsch D, Meijer J et al (2012) β-Ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 1822(7):1096–1108PubMedCrossRef van Kuilenburg ABP, Dobritzsch D, Meijer J et al (2012) β-Ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 1822(7):1096–1108PubMedCrossRef
go back to reference van Lenthe H, van Kuilenburg ABP, Ito T et al (2000) Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips. Clin Chem 46(12):1916–1922PubMed van Lenthe H, van Kuilenburg ABP, Ito T et al (2000) Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips. Clin Chem 46(12):1916–1922PubMed
go back to reference Vreken P, van Kuilenburg ABP, Hamajima N et al (1999) cDNA cloning, genomic structure and chromosomal localization of the human BUP-1 gene encoding beta-ureidopropionase. Biochim Biophys Acta 1447(2–3):251–257PubMedCrossRef Vreken P, van Kuilenburg ABP, Hamajima N et al (1999) cDNA cloning, genomic structure and chromosomal localization of the human BUP-1 gene encoding beta-ureidopropionase. Biochim Biophys Acta 1447(2–3):251–257PubMedCrossRef
go back to reference Wasternack C (1980) Degradation of pyrimidines and pyrimidine analogs–pathways and mutual influences. Pharmacol Ther 8(3):629–651PubMedCrossRef Wasternack C (1980) Degradation of pyrimidines and pyrimidine analogs–pathways and mutual influences. Pharmacol Ther 8(3):629–651PubMedCrossRef
go back to reference Yaplito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, van Kuilenburg ABP (2008) Beta-ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Mol Genet Metab 93(2):190–194PubMedCrossRef Yaplito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, van Kuilenburg ABP (2008) Beta-ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Mol Genet Metab 93(2):190–194PubMedCrossRef
Metadata
Title
Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation
Authors
Yoko Nakajima
Judith Meijer
Doreen Dobritzsch
Tetsuya Ito
Rutger Meinsma
Nico G. G. M. Abeling
Jeroen Roelofsen
Lida Zoetekouw
Yoriko Watanabe
Kyoko Tashiro
Tomoko Lee
Yasuhiro Takeshima
Hiroshi Mitsubuchi
Akira Yoneyama
Kazuhide Ohta
Kaoru Eto
Kayoko Saito
Tomiko Kuhara
André B. P. van Kuilenburg
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 5/2014
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-014-9682-y

Other articles of this Issue 5/2014

Journal of Inherited Metabolic Disease 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.